There are hardly any drugs against ALS. A new study shows that a substance acting on the MAPK signaling pathway may be effective against the neurodegenerative disease: After treatment with trametinib, ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Clene (CLNN) announced that it recently received written guidance from the Division of Neurology 1, DN1, of the U.S. Food and Drug Administration regarding a potential accelerated approval pathway for ...

The pathway leading to the telltale sign of ALS, protein aggregation in the cytoplasm of motor neurons, has been revealed. Researchers from the University of California – San Diego (CA, USA) have ...

Pictured are nuclei of induced pluripotent stem cell (iPSC)-derived motor neurons stained for contrast. The nucleus on the left has been treated with DMSO (control) and appears mostly blue. The ...